期刊文献+

EGFR在骨肉瘤中的表达、基因扩增及其临床意义 被引量:5

The Expression of EGFR Protein,Gene Amplification and Its Clinical Significance in Osteosarcoma
下载PDF
导出
摘要 目的探讨表皮生长因子受体(epidermal growth factor receptor,EGFR)在骨肉瘤中的蛋白表达及基因扩增,并评估其在骨肉瘤发生、发展和预后中的价值。方法以石蜡包埋组织芯片为材料,分别采用免疫组织化学PV-9000两步法与荧光原位杂交(fluorescent in situ hybridization,FISH)技术检测32例骨肉瘤及10例骨软骨瘤中EGFR蛋白表达及基因扩增。结果 EGFR蛋白在骨肉瘤、骨软骨瘤中的表达阳性率分别为84.4%、20.0%;扩增阳性率分别为75%、20%;骨肉瘤中EGFR蛋白表达、基因扩增阳性率与骨软骨瘤相比较,差异具有统计学意义(P<0.05);在骨肉瘤中EGFR蛋白表达、基因扩增阳性率与患者的年龄、性别、肿瘤部位无相关性(P>0.05),与肿瘤转移、临床分期相关(P<0.05)。结论 EGFR与骨肉瘤的发生、发展有关,可以将其作为判断骨肉瘤生物学行为的重要参考指标。 Objective To investigate the expression of EGFR protein and gene amplification in osteosarcoma and evalua-tion of EGFR in osteosarcoma occurrence,development and prognosis. Methods PV-9000 two step method and in situ chemi-cal hybridization(FISH)were used to detect the expression of EGFR protein,gene amplification in 32 cases of osteosarcoma and 10 cases of osteochondroma in paraffin-embedded tissue chip material. Results The positive rate of EGFR expresion in osteosarcoma,osteochondroma were 84. 4% 、20. 0% . The positive rate of EGFR gene amplification were 75% and 20% . There were significant differences between osteosarcoma and osteochondroma in the expression and amplification of EGFR. The ex-pression and amplification of EGFR in osteosarcoma had no correlation with age ,gender ,or the location of the tumor( P 〉0. 05),but were correlated with metastasis and clinical stage(P〈0. 05). Conclusion EGFR is closely related to the occur-rence and development of osteosarcoma,and can be considered as an important index for determing the biological behavior of osteosarcoma.
出处 《实用骨科杂志》 2015年第4期328-330,375,共4页 Journal of Practical Orthopaedics
关键词 骨肉瘤 表皮生长因子受体 免疫组织化学 荧光 osteosarcoma EGFR immunohistochemistry fluorescence
  • 相关文献

参考文献13

  • 1Green JT,Mills AM. Osteogenic tumors of bone[ J]. Se- rain Diagu Patho1,2014,31 ( 1 ) :21-29.
  • 2Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment - where do we stand A state of the art review [ J ]. Cancer Treat Rev ,2014,40 (4) : 523-532.
  • 3Wang J, Yu JM, Jing SW, et al. Relationship between EGFR Over-expression and Clinicopathologic Character- istics in Squamous Cell Carcinoma of the Esophagus : A Meta-analysis[ J]. Asian Pac J Cancer Prev,2014,15 (14) :5889-5893.
  • 4Kishiki T, Ohnishi H, Masaki T,et al. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in me- tastatic colorectal cancer with KRAS mutation [ J ]. On- col Rep,2014,32( 1 ) :57-64.
  • 5Fiala O, Pesek M, Finek J, et al. Retreatment with erlo- tinib of a patient with metastatic NSCLC harboring EG- FR mutation : a case report [ J ]. Tumori, 2014,100 ( 3 ) : 70-73.
  • 6Ayyappan S, Prabhakar D, Sharma N. Epidermal growth factor receptor (EGFR)-targeted therapies in esopha- gogastric cancer [ J ]. Anticancer Res, 2013,33 ( 10 ) : 4139-4155.
  • 7Bi WW, Zhang WH, Yin GH, et al. Analysis of In- doleamine 2-3 Dioxygenase (IDO) and EGFR Co- ex- pression in Breast Cancer Tissue by Immunohistochem- istry[ J]. Asian Pac J Cancer Prey,2014, 15 (14) : 5535-5538.
  • 8Fukazawa EM, Baiocchi G, Soares FA,et al. Cox-2, EG- FR, and ERBB-2 expression in cervical intraepithelial neoplasia and cervical cancer using an automated ima- ging system [ J ]. Int J Gynecol Pathol, 2014,33 ( 3 ) : 225-234.
  • 9Zhou X,Hu Y, Dai L, Wang Y, et al. MicroRNA-7 in- hibits tumor metastasis and reverses epithelial-mesen- chymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer [ J ]. PLoS One,2014,9(5) :e96718.
  • 10Wong MH, Xue A, Julovi SM, et al. Cotargeting of epi- dermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocareinoma[ J ]. Clin Cancer Res ,2014,20 ( 15 ) :4047 -4058.

同被引文献37

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部